Results 241 to 250 of about 35,569 (305)

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial. [PDF]

Nat Commun
Wang H, Ko H, Leung TW, Huang J, Sai J, Liang Y, Li H, Zhang J, Cao Q, Zang W, Li Y, Ma SH, Lui WT, Choi J, Chan C, Wong J, Kwok AJ, Ma K, Fan F, Chan A, Ip V, Leung H, Soo Y, Wong KT, Lai B, Chu CM, Leung HS, Hui A, Cheung T, Abrigo J, Li SH, Chan L, Yeung J, Pan S, Yip T, Lui LT, Hung T, Tsang SF, Leng X, Lam B, Mok VCT, Chan RHM, Nguyen TN, Hu W, Che F, Ip BY.   +45 more
europepmc   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States. [PDF]

J Manag Care Spec Pharm
Akpan N, Zhou B, Rasu RS, Sambamoorthi U.   +3 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Global Spine J
Ibrahim S, Durrani A, Ibrahim MT, Kuttner N, Glivar P, Singh VK, Yu E.   +6 more
europepmc   +1 more source

Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify the incremental economic and utilization burden of comorbid obstructive sleep apnea (OSA) within an overweight to severely obese adult population. Material and Methods This retrospective cohort study utilized 2016–2025 IQVIA PharMetrics Plus Closed Health Plan commercial claims data to identify overweight to severely obese ...
Hyung Seok John Kim, Tien Hoang Tran, Christopher N. Schmickl, Julia F. Slejko   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Decreased Incidence of Carpal Tunnel Syndrome in Patients With Type 2 Diabetes: A Propensity-Matched Analysis. [PDF]

Hand (N Y)
Stump K, Centeno D, Talsania A, Morar H, Wiekrykas B.   +4 more
europepmc   +1 more source

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source

Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents. [PDF]

Diabetes Metab J
Wang SY, Stofer R, Wang H, Brent GA, Shi L, Cai Y, Roosan M, Moin T.   +7 more
europepmc   +1 more source